Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Food inflation affects eating and shopping. Students still get bulk deals, but are people trading down? Debate on price gouging and retailer control persists.
Arc'teryx CEO Stuart Haselden gives an exclusive look inside the outdoor sportswear brand's new NYC flagship store and introduces new MO/GO wearable hiking tech
The US Open kicks off in NYC, and USTA Chairman Dr. Brian Hainline discusses tennis’s growth, Djokovic's worries about pickleball, and the sport's future.
Hero Bread's viral low-carb, keto-friendly croissant, backed by celebrity investors like Tom Brady and Kevin Durant, is revolutionizing healthy eating.
Fed Chair Jerome Powell's Jackson Hole speech on Friday is expected to align with market expectations of upcoming rate cuts, likely beginning in September.